DETAILED AGENDA

Sunday, February 9
Stephenson Cancer Center

5:30-6:00  Welcome Reception
Stephenson Cancer Center, 5th Floor

6:00-6:05  Opening Remarks
Danny Dhanasekaran, PhD
Director, Stephenson COBRE & Center for Basic Cancer Research
Deputy Director for Basic Research
Peggy and Charles Stephenson Cancer Center
Professor and Samuel Roberts Noble Foundation Endowed Chair in
Cancer Research
University of Oklahoma Health Sciences Center
Charlotte Jackson Seminar Room

6:05-6:50  Keynote Address
Reversible Post-Translational Modifications and Cell Signaling in Cancer
Tony Hunter, PhD
American Cancer Society Professor
Professor, Molecular and Cell Biology Laboratory
Renato Dulbecco Chair in Cancer Research
Director, Salk Institute Cancer Center
Salk Institute for Biological Studies
Charlotte Jackson Seminar Room

6:50-7:20  Stephenson COBRE Distinguished Speaker Lecture
Targeting ERK Mitogen-Activation Protein Kinase Signaling for Cancer Treatment
Channing Der, PhD
Professor, Pharmacology
UNC Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Charlotte Jackson Seminar Room

7:30  Dinner
Stephenson Cancer Center, 1st Floor
Monday, February 10
Samis Family Education Center
All Sessions – Level Two, Auditorium

7:30-8:20  Breakfast and Registration
Samis Center, Level Two

8:20-8:30  Welcome Address
Robert Mannel, MD
Director, Stephenson Cancer Center
Professor, Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center

8:30-10:10  Session 1: Ovarian Cancer Pathobiology
Session Chair: Yong Sang Song, MD, PhD

8:30-8:50  The Role of the Imprinted Tumor Suppressor Gene DIRAS3 (ARHI) in Regulating Ovarian Cancer Cell Growth, Motility, Autophagy and Tumor Dormancy
Robert Bast, MD

8:50-9:10  Mouse Models of High-Grade Serous Carcinoma: Fallopian Tube and Ovarian Origins
Martin Matzuk, MD, PhD

9:10-9:30  The Nuclear RhoGEF Ect2, A Driver of Ovarian Cancer Cell Transformation
Adrienne Cox, PhD

9:30-9:50  Context-Dependent Actions of Progesterone Receptors Mediate Distinct Cell Biologies in Ovarian Relative to Breast Cancer Models
Carol A. Lange, PhD

9:50-10:10  Integrative Analysis of microRNA and their Target mRNA for Ovarian Cancer Subtype Classification
Taesung Park, PhD

10:10-10:25  Coffee Break
Samis Center, Level Two

10:25-12:05  Session 2: Ovarian Cancer: Clinical Challenges
Session Chairs: Byoung-Gie Kim, MD, PhD and Emmett Vance Schmidt, MD, PhD

10:25-10:45  Targeting Ovarian Cancer
Scott McMeekin, MD

10:45-11:05  Clinical Trial Design and Endpoints in Ovarian Cancer
Robert Coleman, MD
11:05-11:25  Phase I Experience with an Ovarian Cancer Population
Kathleen Moore, MD

11:25-11:45  The Role of Angiogenesis Inhibition in the Treatment of Ovarian Cancer: A Clinician's Point of View
Katherine Moxley, MD

11:45-12:05  Therapeutic Rationale for Targeting TGF-β Signaling to Control Cancer Metastasis and Stemness
Seong-Jin Kim, PhD

12:05-12:50  Lunch
Samis Center, Level One

12:50-2:10  Session 3: Ovarian Cancer Metabolomics
Session Chair: Benjamin Tsang, PhD

12:50-1:10  Metabolic Dependency of Cancer Cells on Tumor Microenvironment in Epithelial Ovarian Cancer
Yong Sang Song, MD, PhD

1:10-1:30  Genomic Analysis of Ovarian Cancer Metastasis: Towards Improved Understanding and Treatment
John McDonald, PhD

1:30-1:50  Genetic and Epigenetic Regulation of Autophagy in Ovarian Cancer
Ciro Isidoro, DSc, MD

1:50-2:10  The Missing Link between Lipid Droplets and Autophagy in Ovarian Cancer
Vijayalakshmi Shridhar, PhD

2:10-2:25  Coffee Break
Samis Center, Level Two

2:25-4:05  Session 4: Tumor Microenvironment
Session Chair: Young-Joon Surh, PhD

2:25-2:45  The Role of Host Cells in Regulating Ovarian Cancer Chemoresistance and CSC Fate
Ronald Buckanovich, MD, PhD

2:45-3:05  Reactive Tumor Stroma
Sandra Orsulic, PhD

3:05-3:25  Peritoneal Microenvironment – Hypoxia-Induced Ovarian Cancer Cell Seeding and Metastasis
Sundaram Ramakrishnan, PhD

3:25-3:45  Stromal Fibroblasts – and Cancer-Derived Microenvironments in Cancer Progression
          Jinsong Liu, MD, PhD

3:45-4:05  The Ovary: Stem Cell Source and Cell Transformer Inducer
          Jeong Mook Lim, DVM, PhD

4:05-4:20  Coffee Break
          Samis Center, Level Two

4:20-5:40  **Session 5: Cancer Chemoprevention**
          Session Chair: Ciro Isidoro, DSc, MD

4:20-4:40  Anti-Inflammatory Natural Products with Cancer Chemoprevention Potential
          Young-Joon Surh, PhD

4:40-5:00  Cancer Prevention: New Directions and Opportunities
          Zigang Dong, MD, Dr PH

5:00-5:20  Genistein and Lycopene in the Prevention of Genitourinary Tumors
          Omer Kucuk, MD

5:20-5:40  Natural Compounds as Inhibitors of the 10 Hallmarks of Cancer
          Marc Diederich, PhD
Tuesday, February 11
Samis Family Education Center
All Sessions – Level Two, Auditorium

7:30-8:30  Breakfast and Registration
           Samis Center, Level Two

8:30-9:00  The Samuel Roberts Noble Foundation Lecture
           Targeting RAS Signaling by Small Molecule Inhibitor, Rigosertib
           E. Premkumar Reddy, PhD
           Director of Experimental Cancer Therapeutics
           Professor, Departments of Oncological Sciences and Structural and
           Chemical Biology
           Mount Sinai School of Medicine

9:00-10:40 Session 6: Tumor Microenvironment and Angiogenesis
              Session Chair: Channing Der, PhD

9:00-9:20  Microenvironment Regulation of the Cancer Stem Cell State,
           Implications for Therapeutic Intervention
           David Cheresh, PhD

9:20-9:40  Controlling Escape from Angiogenesis Inhibitors
           Donald McDonald, MD, PhD

9:40-10:00 Tumor-Related Tetraspanins CD82 and CD151 Regulates Vascular
              Morphogenesis and Stability
              Xin Zhang, MD, PhD

10:00-10:20 VCAM-1 and Ovarian Cancer Metastasis
              Jill Slack-Davis, PhD

10:20-10:40 How Cancer Cells use ER Stress and Autophagy to Eat Stroma
              Doris Benbrook, PhD

10:40-10:55 Coffee Break
              Samis Center, Level Two

10:55-12:35 Session 7: Targeted Therapy I
              Session Chair: Sundaram Ramakrishnan, PhD

10:55-11:15 Defective Homologous Recombination and Therapeutic Opportunities
           in Ovarian Cancer
           Jeff Boyd, PhD

11:15-11:35 Network Analysis Identifies an HSP90 Central Signaling Hub
           Susceptible in Ovarian Cancer
           Denise Connolly, PhD
11:35-11:55  Next Generation X-Aptamers for Personalized Nanomedicine in Ovarian Cancer  
David Gorenstein, PhD

11:55-12:15  Piceatannol Enhances Cisplatin Sensitivity in Gynecologic Cancer by Modulating p53, XIAP, and Mitochondrial Fission  
Benjamin Tsang, PhD

12:15-12:35  Redox Regulation and Drug Resistance in Ovarian Tumors: Targeting Gamma-Glutamyl Transpeptidase  
Marie Hanigan, PhD

12:35-1:15  Lunch  
Samis Center, Level One

1:15-2:55  Session 8: Target Discovery  
Session Chair: Sandra Orsulic, PhD

1:15-1:35  Production of Transgenic Aves for Animal Model Development  
Jae Yong Han, PhD

1:35-1:55  BMI-1 and Ovarian Cancer  
Resham Bhattacharya, PhD

1:55-2:15  Targeting EF2K as Novel Therapeutic Modality for Ovarian and Triple Negative Breast Cancer  
Bulent Ozpolat, MD, PhD

2:15-2:35  Oncogenic Signaling by Lysophosphatidic Acid  
Danny Dhanasekaran, PhD

2:35-2:55  JMJD2A: A Potential Novel Target in Cancer  
Ralf Janknecht, PhD

2:55-3:10  Coffee Break  
Samis Center, Level Two

3:10-4:50  Session 9: Targeted Therapy II  
Session Chair: Marc Diederich, PhD

3:10-3:30  Targeting p53-FoxM1 Axis in Ovarian Cancer  
Jeremy Chien, PhD

3:30-3:50  In Vitro and In Vivo Application of Anti-Cotinine Antibody and Cotinine-Conjugated Compounds  
Junho Chung, MD, PhD

3:50-4:10  Targeted Inhibition of FAK, PYK2 and BCL-XL Synergistically Enhances Apoptosis in Ovarian Clear Cell Carcinoma Cell Lines
Byoung-Gie Kim, MD, PhD

4:10-4:30 Aptamer Therapeutic for Breast Cancer Treatment and Metastasis
Takemi Tanaka, PhD

4:30-4:50 Self-Therapeutic Nanoparticle
Priyabrata Mukherjee, PhD

4:50 **Concluding Remarks**
Yong Sang Song, MD, PhD
Director, Cancer Research Institute
Chairman, Cancer Biology Interdisciplinary Program
Director, Gynecologic Oncology
Professor, Obstetrics and Gynecology
Seoul National University
Seoul, S. Korea